INTRODUCTION AND OBJECTIVES: Determine the association of Testosterone Replacement Therapy (TRT) with event free survival and absolute risk of hepatotoxicity, thromboembolic cardiovascular events, and obstructive sleep apnea (OSA) in a cohort of healthy adult men using TRT.
METHODS: We queried the TRICARE military database, which comprises all retired and active duty men and women and their immediate family members, who receive insurance through the military. Men age 18-65, diagnosed with hypogonadism who received TRT between 2006-2010 were included. We compared event-free survival and absolute risk of hepatotoxicity, thromboembolic and cardiovascular events, and obstructive sleep apnea (OSA) between men using TRT and controls.
RESULTS: Relative to controls, patients using TRT had improved cardiovascular event free survival (p¼0.004). There was no significant difference in event free survival for hepatotoxicity (p¼0.345), and thromboembolic events (p¼0.239). Absolute two-year risk for men using TRT was 0.02 for hepatotoxicity, 0.06 for Cardiac events, 0.02 for thromboembolic events and 0.17 for Sleep Apnea. Absolute 2-year risk was similar with the exception with OSA, which had higher 2-year absolute risk (95% CI: 1.56%-1.84% of TRT users vs. 1.1%-1.4% in controls).
CONCLUSIONS: In our cohort of there was no significant increase in risk of hepatotoxicity, and thromboembolic complications among men using TRT. Additionally, men using TRT had modestly prolonged cardiovascularevent-free survival. Prior studies suggesting elevated risk of cardiovascular effects may be less generalizable to healthy young men using TRT in a community setting. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1219
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